Thiazolidinedione (TZD) activates the peroxisome proliferator-activator receptor gamma (PPARγ) and improves insulin resistance and has been used for lowering blood glucose in patients with type 2 diabetes mellitus. Here, PPARG is linked to type 2 diabetes mellitus.